

The Future of Checkpoint Inhibition in Cancer: Are We About to Challenge the Standard of Care Across Multiple Solid Tumors? (Breast, Gastric, Genitourinary, and Colorectal Cancers)

Sunday, 9 October 2016
18:30 – 20:00

Bella Center Copenhagen
Brussels Auditorium
Copenhagen, Denmark

Chair: Luis A. Diaz (USA)

Industry
Satellite Symposium
Sponsored by MSD

CHAIR

Luis A. Diaz, Jr.

Associate Professor of Oncology
Johns Hopkins University
Baltimore, Maryland, USA

FACULTY

Arjun V. Balar

Assistant Professor, Department of Medicine
Co-Leader, Genitourinary Cancers Program,
Division of Hematology & Oncology
New York University Cancer Institute,
NYU Langone Medical Center
New York, New York, USA

Markus Möhler

Professor of Gastrointestinal Oncology
Johannes-Gutenberg University
Mainz, Germany

Michael Untch

Professor
Head of the Clinic for Gynecology,
Gynecologic Oncology and Obstetrics
Head of the Interdisciplinary Breast
Cancer Center
HELIOS Clinic
Berlin, Germany

Educational Objectives:

- Provide a future perspective on potential integration of anti-PD-1 therapy, as monotherapy and in combination with other treatments, in routine clinical practice
- Review key findings on use of these agents that may optimize future use in patients, and potentially improve future treatment success
- Effect a better understanding of future treatment algorithms by patient type

AGENDA

18:30 – 18:35	Welcome and Introductions	Luis Diaz
18:35 – 18:50	Tumor Immunology and the Role of Checkpoint Inhibitors	Luis Diaz
18:50 – 19:05	The Potential Role of Checkpoint Inhibitors in the Treatment of Colorectal and Gastric Cancers – What Is Exciting and What Questions Need to be Addressed?	Markus Möhler
19:05 – 19:20	Immunotherapy in Genitourinary Cancers: Results and Ongoing Clinical Trials	Arjun Balar
19:20 – 19:35	The Emerging Potential of Checkpoint Inhibitors in the Treatment of Breast Cancer	Michael Untch
19:35 – 19:50	Management of Patients Receiving Checkpoint Inhibitors	Markus Möhler
19:50 – 20:00	Q&A and Closing Remarks	Luis Diaz

Presentations and patient cases were independently prepared by the speakers with no influence of MSD.